健玛博 GMAB
$53.63 +$0.89 (+1.69%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $53.89 +0.48%
开盘$52.36
昨收$52.74
当日区间$51.22 – $54.15
成交量7.83M
市值$33.47B
市盈率（TTM）45.8
股息率–
GMAB 相关新闻
匹配 Genmab 或代码 GMAB 的头条新闻，按最新排序。
- H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
- A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $35 to $43
- William Blair Maintains Genmab(GMAB.US) With Buy Rating
- Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
- Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)
- Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33
- TD Cowen Upgrades Genmab(GMAB.US) to Buy Rating, Raises Target Price to $43 正面
- H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $40 正面
- TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32
- A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40
- Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)
- H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $38
- Wells Fargo Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
- Wolfe Research Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $32
- Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $33 负面
暂无评论——快来第一个聊聊 GMAB。